Table 3.

Incremental quality-adjusted-life-years converting from the current second-line treatment (e.g., sulfonylurea) to MCDA recommended treatment

Drug class	NHANES Population, %	Incremental QALYs (95% CI) Base-case network meta- analysis22	Incremental QALYs (95% CI) Sensitivity analysis (incorporating results from recent trials42)
All persons	100.0	0.036 (0.032, 0.039)	0.064 (0.061, 0.067)
Age
20-39	6.9	0.009 (0.004, 0.014)	0.014 (0.009, 0.019)
40-59	28.5	0.024 (0.020, 0.028)	0.034 (0.030, 0.037)
60+	64.6	0.043 (0.038, 0.048)	0.082 (0.077, 0.087)
Sex
Male	50.3	0.042 (0.037, 0.048)	0.078 (0.073, 0.083)
Female	49.7	0.028 (0.024, 0.033)	0.049 (0.045, 0.053)
Race
Black	50.2	0.038 (0.033, 0.043)	0.070 (0.066, 0.074)
Non-Black	48.8	0.033 (0.028, 0.037)	0.058 (0.054, 0.062)
Diabetes duration
< 10 years	56.6	0.034 (0.030, 0.038)	0.058 (0.054, 0.062)
≥10 years	43.4	0.037 (0.031,0.043)	0.071 (0.066, 0.076)
HbA1c
< 6.5%	38.8	0.028 (0.021, 0.033)	0.058 (0.053, 0.063)
6.5% – 7.9%	40.3	0.038 (0.032, 0.044)	0.069 (0.064, 0.074)
8.0% - 9.4%	12.5	0.040 (0.030, 0.049)	0.066 (0.057, 0.075)
≥ 9.5%	8.4	0.052 (0.041, 0.063)	0.063 (0.052, 0.074)
10-year cardiovascular risk (myocardial infarction or stroke)
< 10%	41.6	0.018 (0.014, 0.021)	0.030 (0.026, 0.034)
10% – 20%	36.5	0.037 (0.031, 0.044)	0.071 (0.065, 0.077)
≥ 20%	21.9	0.066 (0.056, 0.076)	0.118 (0.108, 0.128)
10-year composite Microvascular disease risk
< 20%	30.0	0.018 (0.014, 0.023)	0.033 (0.029, 0.037)
20% – 30%	35.9	0.029 (0.024, 0.035)	0.059 (0.053, 0.065)
≥ 30%	34.1	0.057 (0.049, 0.064)	0.096 (0.089, 0.107)